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ABSTRAK 
 
Latar belakang: Pengagihan 18F-FDG dalam imbasan PET-CT adalah berdasarkan kepada 
keperluan glukosa oleh sel-sel. Pengambilan 18F-FDG yang banyak oleh sel-sel yang 
mempunyai metabolisma aktif seperti sel otot licin usus mampu menjejaskan tafsiran imej. 
Kajian ini menilai keberkesanan Mebeverine (Duspatalin) dan Hyoscine-n-butylbromide 
(Buscopan) dalam mengurangkan pengambilan 18F-FDG secara fisiologi oleh usus ketika 
imbasan 18F-FDG PET-CT dijalankan. 
Kaedah: Sebuah kajian prospektif rawak telah dijalankan kepada 195 pesakit yang menjalani 
imbasan PET-CT di antara September 2016 hingga Februari 2017. Mereka dibahagikan kepada 
3 kumpulan; 62 pesakit menerima 135mg ubat Mebeverine, 68 pesakit menerima 10mg ubat 
Hyoscine-n-butylbromide manakala 65 pesakit adalah kumpulan kawalan. Semua pesakit 
diimbas antara 45 minit ke 1 jam selepas suntikan 18F-FDG. Seorang pakar perubatan nuklear 
telah menganalisa imej imbasan; SUVmean untuk usus dan nisbah SUVmean usus : hati telah 
diperolehi untuk analisis statistik. 
Keputusan: Nilai purata SUVmean dan nisbah SUVmean usus:hati di dalam ketiga-tiga kumpulan 
adalah hampir sama. Tiada perbezaan yang signifikan antara purata SUVmean dan nisbah 
SUVmean usus:hati di dalam ketiga-tiga kumpulan (p>0.050). Analisis kualitatif ke atas tahap 
pengambilan 18F-FDG oleh usus dan kesukaran mentafsir imej dalam ketiga-tiga kumpulan 
adalah tidak signifikan (p=0.302 dan p=0.957 masing-masing). Terdapat perkaitan yang positif 
antara tahap pengambilan 18F-FDG dan kesukaran mentafsir imej (r=0.332, p<0.001). 
Kesimpulan: Tiada kesan yang signifikan oleh Mebeverine dan Hyoscine-n-butylbromide 
dalam pengurangan pengambilan 18F-FDG oleh usus secara fisiologi semasa imbasan PET-CT. 
Semakin tinggi tahap pengambilan 18F-FDG dalam usus, semakin sukar untuk menafsir imej 
imbasan. 
Katakunci: 18F-FDG PET-CT, pengambilan 18F-FDG oleh usus, Mebeverine, Duspatalin, 
Hyoscine-n-butylbromide, Buscopan, kesan antispasmodik. 
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ABSTRACT 
 
Background: 18F-FDG distibution in PET-CT scan is based on glucose avidity of the cells. 
Intense accumulation of 18F-FDG in in the cells with active metabolism like smooth muscles in 
the bowel can affect the image interpretation. The aim of this study is to determine the effects of 
Mebeverine (Duspatalin) and Hyoscine-n-butylbromide (Buscopan) in the reduction of 
physiological bowel uptake in 18F-FDG PET-CT scan. 
Methodology: A prospective randomised controlled trial was conducted for 195 patients whom 
attended PET-CT scan between September 2016 and February 2017. They were divided into 3 
groups; 62 patients received 135mg of oral Mebeverine, 68 patients received 10mg of oral 
Hyoscine-n-butylbromide and 65 patients were in the control group. All patients were scanned 
45 minutes to 1 hour after injection of 18F-FDG. An independent experienced interpreter 
reviewed the images; SUVmean of bowel and bowel-to-liver ratio were obtained for statistical 
analysis. 
Results: There were almost equal values of mean SUVmean of bowel and bowel-to-liver ratio in 
all groups. No significant different in mean SUVmean of bowel and bowel-to-liver ratio among 
the three groups  (p>0.050). There was no significant association of degree of bowel uptake and 
difficulty of image interpretation in all the three groups (p=0.302 and p=0.957 respectively). 
There was positive relationship between degree of bowel uptake and difficulty of image 
interpretation (r=0.332, p<0.001). 
Conclusion: There was no significant effect of Mebeverine and Hyoscine-n-butylbromide to 
reduce physiological bowel uptake in 18F-FDG PET-CT. The higher the degree of bowel 
uptake, the more difficult for the interpreter to interpret the images. 
Keywords: 18F-FDG PET-CT, physiological bowel uptake, Mebeverine, Duspatalin, 
Hyoscine-n-butylbromide, Buscopan, antispasmodic effect. 
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CHAPTER 1 
INTRODUCTION 
 
Positron Emission Tomography (PET) imaging was introduced in the field of 
nuclear medicine since 1974 with the capability of assessing functional/physiological 
status of a disease by using radioisotope. Over the years, its use especially in oncology 
cases has been widely accepted (Rohren et al, 2004). However, it was limited due to 
lack of anatomical identification (Lind et al, 2004). The difficulty in localisation of the 
18F-FDG uptake in PET is due to poor spatial resolution (Townsend, 2004 and Moses, 
2011).  
 
Computed tomography on the other hand has the ability to demonstrate good 
anatomy but lack in functional evaluation. In view of that, new advancement has been 
introduced in 1998 by combining PET imaging and CT imaging to form a hybrid 
imaging called PET-CT. The ability of PET-CT imaging to evaluate the functional and 
anatomical findings has helped in improving diagnostic accuracy (Von Schulthess, 
2006). Furthermore, PET-CT scan also able to evaluate physiological 18F-FDG uptake. 
This is important because some uptake appears to be physiological in PET but CT 
evaluation found pathology at the uptake site (Kostakoglu et al, 2004). The ability to 
evaluate pathological and physiological findings has helped to improve patient 
management (Bar-Shalom et al, 2003). 
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However, some 18F-FDG uptake is difficult to be interpreted such as 
physiological uptake in the smooth muscles of bowel. Gastrointestinal tract uptake 
among others is the commonest site of uptake in PET-CT. High 18F-FDG uptake in the 
bowel might be due to active bowel movement. In view of this, it may mask any 
underlying bowel related pathology. 
 
It is more challenging to interpret the image when the primary lesion originated 
from the bowel or any organ adjacent to the bowel. As a result, the use of antispasmodic 
agent such as Mebeverine (Duspatalin) and Hyoscine-n-butylbromide (Buscopan) was 
introduced. Studies done looking into the use of these agents prior to PET-CT scan have 
noted reductions in the physiological 18F-FDG uptake in the bowel. However, there is 
no consensus as to which of this agent is to be used prior to the scan. Therefore, the aim 
of this study is to assess the effectiveness of both agents in reducing the physiological 
uptake in the bowel. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
CHAPTER 2 
LITERATURE REVIEW 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1  Brief background of PET-CT 
 
 PET imaging concept is based on detecting the distribution of radiotracer in the 
body. Since the day of PET was introduced, there are many types of radiotracer 
available. The distribution of the radiotracer reflects the physiology of the disease. For 
example, 18F-fluorodeoxyglucose, 18F-fluorothymidine, 11C-methionine, 11C-choline 
and 18F-fluoride. Commonly, the radioisotope is tagged to a molecule that undergoes 
metabolism within the cells. For example, radioisotope 18-Fluorine is a positron 
emitter. It is tagged to fluorodeoxyglucose (FDG) which is a glucose analogue that will 
be distributed in the body to areas in which there is high glucose consumption by the 
cells e.g. in inflammation, infection, physiological such as brain as well as cancer cells. 
18F-FDG is transported into the cells via glucose transporter proteins (GLUT). Then, it 
will undergo a phosphorylation process by hexokinase (Figure 2.1.1). The end product 
of this is 18F-FDG-6-phospate. Phosphorylated 18F-FDG is chemically impermeable to 
cell membrane and therefore does not undergo further metabolism. It will remain 
trapped in the cell (Paulwels et al, 1998). 
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Figure 2.1.1: Schematic diagram on the metabolic trapping of 18F-FDG in the cells and 
glucose metabolism pathway. HK – hexokinase, G6Pase – glucose-6-phospatase, 18F-
FDG6P – 18F-FDG-6-phospate, G6P – glucose-6-phospate 
 
 As 18-Fluorine decays, it emits positron, which will undergo annihilation 
process with electron. Annihilation of positron-electron produces two annihilation 
photons travelling back-to-back (Figure 2.1.2). The amount of energy of each photon is 
511 keV. The PET scanning machine detects these photons and processes it to form 
PET images. The areas with high affinity to glucose will accumulate higher amount of 
18F-FDG, thus the amount of annihilation photons is higher in this areas. As a result, 
areas of high 18F-FDG uptake will be seen in the image later. In the areas whereby 
there is high glucose metabolism, both physiological and pathological sites appear 
increased in uptake that requires precaution during image interpretation. 
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Figure 2.1.2: PET concept of detection of the coincidence annihilation photon that 
travel back-to-back of 511 keV energy. 
 
 The role of PET especially in clinical oncology has increased over the years 
(Beyer et al, 2000). Introduction of PET-CT later has provided a new dimension of 
imaging whereby function and anatomy can be assessed together. PET-CT imaging has 
role in diagnosis, staging, restaging as well as monitoring treatment response in 
oncology. Furthermore, it helps in the condition whereby the primary lesion is 
unknown. PET-CT is also able to detect suitable site of biopsy. A study evaluates the 
role of PET-CT in restaging Hodgkin lymphoma whereby they found that PET-CT has 
detected bone marrow involvement despite negative bone marrow trephine biopsy 
report (Moulin-Romsee et al, 2010). The upstaging of the disease is important as the 
patients had to change to another treatment protocol. 
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2.2  Pitfalls in PET-CT image interpretation 
 
 18F-FDG is distributed based on glucose avidity. Different organs have different 
glucose requirement. Brain has the highest 18F-FDG avidity due to high glucose 
consumption by the brain cells. Myocardium will exhibit high 18F-FDG avidity due to 
high glycolytic metabolism during the non-fasting state. Variable uptake intensities are 
sometimes seen in the myocardium despite 4-18 hours of fasting (Shreve et al, 1999). 
Besides physiological metabolism, intense uptake is also seen in the urinary system as a 
result of 18F-FDG excretion. 18F-FDG activity is high in the collecting system of 
kidneys as well as urinary bladder. Liver shows less intense of 18F-FDG activity 
similarly the spleen, bone marrow and renal cortex.  
 
 Tonsils in the neck usually showed high 18F-FDG activity as a result of 
infection/inflammation. Meanwhile, salivary glands uptake is variable (Nakamoto et al, 
2005). Skeletal muscle uptake is also variable depending upon the muscles activity and 
insulin injection prior to 18F-FDG administration. Symmetrical muscle uptake and 
areas with increased muscle contraction such as vocal cord (excessive speech), 
extraocular muscles and neck muscles are likely physiological.  
 
 In the gastrointestinal tract, there are several conditions attributed to high 18F-
FDG uptake such as malignancy and other benign/physiological conditions. Other than 
smooth muscle activity that is due to peristalsis, other benign condition in the bowel 
may also take up 18F-FDG. These conditions include inflammatory process such as 
colitis and duodenitis, infection such as viral and H.pylori infection, bleeding and 
microbial activity. The normal flora in the bowel takes up 18F-FDG that is excreted into 
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the bowel lumen (Renee et al, 2008). Other than that, drug such as metformin also cause 
high 18F-FDG uptake in the bowel (Gontier et al, 2008). Metformin is responsible for 
activation of GLUT-2 on the mucosal surface of the bowel that causes higher avidity of 
glucose in the bowel (Walker et al, 2005). Patient in hyperglycemic state during 18F-
FDG injection will have lower 18F-FDG uptake by the tumor/lesion. Insulin 
administration to lower down the glucose level can be done provided that the 18F-FDG 
injection is delayed few hours later to avoid generalised muscle uptake during PET-CT 
scan (Boellaard et al, 2010) 
 
 Normal peristaltic activity of the bowel may cause 18F-FDG uptake in PET-CT. 
This is termed as physiological uptake. Bowel usually demonstrates variable uptake 
depending on sites. Diffuse low level of uptake usually observed in the small bowel. 
Colon demonstrates a more heterogenous uptake especially at the ileo-caecal junction, 
ascending colon and rectum (Blake et al, 2005). This is attributed to the activity of the 
sphincter and peristaltic activity. Besides that, the higher 18F-FDG uptake in the 
caecum and right colon was also attributed to the abundance of lymphocytes in that 
region (Abouzied et al, 2005). Other study also proposed the high 18F-FDG uptake in 
ascending colon was also related to the presence of lymphocytes (Lee et al, 2009). 
 
 Other conditions that can cause increase bowel activity will also cause higher 
18F-FDG uptake. Patients with bowel related illness such as diarrhoea or constipation 
during the scan time might exhibit high 18F-FDG uptake in the bowel. A case study 
reported diffuse bowel uptake seen in PET-CT in a patient with fever of unknown origin 
and diarrhoea (Nihashi et al, 2006). Pre-treating the patient with purging agent such as 
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senna-glycoside proved that increased bowel motility causes high bowel uptake due to 
increased in bowel peristaltic activity (Soyka et al, 2010).  
 
 Inflammatory reaction attracts and activates inflammatory cells as well as 
various cytokines and chemical mediators. As a result of this, there is increased in 
expression of glucose transporter protein on the cell surface, thus causes high affinity of 
18F-FDG (Love et al, 2005). PET-CT has been used for evaluation of inflammatory 
disease such as Crohn’s disease and found that it showed better sensitivity and 
specificity with a promising value as a non-invasive tool of assessment (Louis et al, 
2007). 
 
 The uptake of 18F-FDG in the bowel appears in variable pattern such as diffuse 
homogenous uptake, heterogenous uptake, focal intense uptake as well as diffuse low 
uptake. Diffuse uptake are likely physiological but there were studies found that certain 
pathology presented as diffuse uptake in PET-CT. Kresnik et al (2002) had reviewed 5 
patients that were diagnosed with colitis. Conventional investigation with magnetic 
resonance colonography, ultrasonography as well as colonoscopy found to be normal 
but PET-CT showed diffuse bowel uptake. Other studies by Gontier et al, (2008) and 
Toriihara et al, (2011) also found the similar pattern. 
 
Hideki et al (2009) had conducted a study to look at the effect of oral contrast on 
bowel uptake in PET-CT scan. This study involved 60 patients underwent PET-CT scan 
for various indications. Half of the patients were given oral contrast prior to PET-CT 
scan, while the other half was the control group. The pattern of 18F-FDG distributions 
	 9	
in the bowel was evaluated. The study found that oral contrast caused focal as well as 
diffuse increased uptake of 18F-FDG in the bowel (Hideki et al, 2009). 
 
 Focal intense uptake of 18F-FDG is more suspicious of pathology especially 
when the corresponding CT image is abnormal. There must be precaution in 
interpreting this lesion as loop of bowel may present like a bowel mass with high 18F-
FDG uptake. Furthermore, certain physiological uptake also presented with focal lesion 
e.g. in constipation (Kim et al, 1999). The interpretation of the image is usually 
ambiguous. In patients with known bowel pathology e.g. in colonic carcinoma the 
image interpretation is really challenging as it may be masked by physiological uptake. 
Zhuang et al, (2002) had reviewed 197 patients referred for PET-CT to evaluate 
pulmonary nodules. Out of these patients, 59 of them had incidental diffuse bowel 
uptake and 17 had focal uptake. Surprisingly, 5 of those with focal bowel uptake turned 
out to be cancerous by histopathological review. Other study also observed the similar 
findings (Israel et al, 2005). 
 
 However, pattern of uptake alone is not indicative of pathological or 
physiological process. A study was conducted to evaluate the clinical significance of 
colonic uptake in patients with known gastric adenocarcinoma involving 239 patients. 
All of them underwent PET-CT scan and colonoscopy. The study found that although 
PET-CT showed intense uptake of 18F-FDG in the colon, correlation with colonoscopy 
and biopsy is still needed to confirm the diagnosis. Semiquantitative evaluation in term 
of maximum standardised uptake value (SUVmax), also showed that there was no 
specific limit of SUVmax to be considered as suspicious of malignancy (Shim et al, 
2012). 
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2.3  Standardised Uptake Value 
 
PET-CT machine measured relative uptake of 18F-FDG in a particular region of 
interest to quantifiy the uptake. This quantification is called standardised uptake value 
(SUV). 
 
 
 
 
 
Figure 2.3.1: Calculation formula for standardised uptake value (SUV)  
                (Ziessman et al, 2014) 
 
There are factors that affect SUV value such as patient size/body mass, 
injection-to-scan time, plasma glucose level, amount of injected dose, region of interest 
and pixel size (Keyes, 1995). As the SUV is calculated to body weight, changes in body 
weight may also change the SUV value.  Similarly, patient with high plasma glucose 
level e.g. uncontrolled diabetes mellitus may compete with 18F-FDG to saturate 
glucose transporter proteins in the body (Ziessman et al, 2014). 
 
The higher SUV value reflects the avidity of the underlying tissues towards 18F-
FDG. Besides that, it is used to evaluate the response of certain disease towards therapy 
(Kinehan & Fletcher, 2010). There are commonly two types of SUV value measured by 
PET-CT machine, which is maximum SUV (SUVmax) and mean SUV (SUVmean). 
SUVmax measures the maximum 18F-FDG uptake in the region of interest corrected to 
							SUV	=		 					Tissue	activity	(millicurie/millilitre)		 	 Injected	dose	(millicurie)/weight	(gram)	
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body weight while SUVmean is the calculated average of 18F-FDG uptake in the region 
of interest corrected to body weight.  
 
As the measurement of SUV is affected by multiple variables, it is suggested to 
improve the reproducibility of SUV value by the use of reference tissue and 
normalization the lesion’s SUV to the reference tissue’s SUV (Kinehan & Fletcher, 
2010). A number of tissues have been used as reference tissue such as mediastinal blood 
pool, liver, lung and cerebellum. The commonest reference tissue is liver and 
mediastinal blood pool. The SUV measurement in normal liver and mediastinum is 
stable over time (Paquet et al, 2004). Therefore, bowel-to-liver ratio is calculated in this 
study.  
 
The concern over SUVmax is that the reported value might be based from a lesion 
of one pixel. Thus, there is potential bias and noise compared to SUVmean. Therefore, 
SUVmean was chosen for semiquantitative analysis in this study. A study done in Korea 
evaluating the effectiveness of Mebeverine in reducing physiological bowel uptake in 
18F-FDG PET-CT also used SUVmean and bowel-to-liver ratio in their analyses (Song et 
al, 2014). Similarly another study done in 2008 looking at the effect of N-
butylscopolamine (Buscopan) in reduction of physiological bowel uptake during PET-
CT scan also used SUVmean and bowel-to-liver ratio (Emmott et al, 2008). 
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2.4  Methods utilised to reduce physiological uptake in the bowel 
 
 Several studies have been conducted previously to look for appropriate measure 
to reduce 18F-FDG uptake in the bowel. However, there is no technique found to 
produce consistent effect till date. The use of purging agent such as senna glycoside has 
shown an increased in 18F-FDG uptake (Soyka et al, 2010). This is explained by 
another study that it is related to its function of increasing bowel secretions 
(Waltenberger et al, 2008). This finding also explained a study by Yamamoto et al 
(2004) whereby gastric secretory inhibitor (Omeprazole) was used to evaluate its 
effectiveness in reducing bowel uptake during 18F-FDG PET-CT. They found that 
introduction of Omeprazole had reduced the physiological bowel uptake (Yamamoto et 
al, 2004). 
 
 However, preparing patient with non-purging agent such as isosmotic fluid does 
help to clear up bowel uptake. Administration of this fluid orally a day before PET-CT 
was found to be beneficial. Isosmotic fluid has helped to improve the sensitivity and 
specificity of the scan (Miraldi et al, 1998). As metformin was found to cause increase 
in bowel uptake (Walker et al, 2005 and Gontier et al, 2008), witholding metformin for 
3 days prior to PET-CT reduced the 18F-FDG uptake in the bowel (Ozulker et al, 
2010). 
 
 Increased in bowel motility causes spasms in the mucosal layer of the 
gastrointestinal tract. Antispasmodic agents such as mebeverine and hyoscine have the 
ability to prevent spasms without interfering the normal gastric peristalsis. In 2014, a 
study was conducted in Korea to look for the effect of Mebeverine in 18F-FDG PET-
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CT scan. Two groups of patients were recruited with total of 161 patients involved. The 
study found that Mebeverine usage in 18F-FDG PET-CT reduced the bowel uptake 
(Song et al, 2014). St. Theresa’s Hospital in Hong Kong reported that the use of 
Mebeverine is their routine protocol during 18F-FDG PET-CT to reduce spasms in the 
gut (Kevin, 2012).  
 
Emmott et al (2008) studied the effect of N-butylscopolamine (Buscopan) in 
reduction of physiological bowel uptake during PET-CT. The study found that N-
butylscopolamine can reduce the bowel uptake and further potentially improves the 
accuracy of 18F-FDG PET-CT reporting. Earlier than that, a study by Stahl et al (2000) 
using N-butylscopolamine also found that it causes reduction in bowel uptake during 
PET scan.  
 
   
 
 
 
 
 
 
 
 
 
 
 
	 14	
2.5 Pharmacology of Mebeverine and Hyoscine-n-butylbromide 
 
Mebeverine (Duspatalin) is a musculotropic antispasmodic agent that has direct 
action on the smooth muscle of the gastrointestinal tract. Its spasmolytic effect is due to 
combination of non-specific depressant and anaesthetic activity together with inhibition 
of sympathetic effect as it has the ability to block noradrenalin uptake. It is rapidly and 
completely absorbed after oral ingestion. It is metabolized completely in the body 
before excretion. It undergoes hydrolysis leading to veratric acid and mebeverine 
alcohol. Both are excreted in the urine. Furthermore, the mebeverine alcohol is formed 
partly as carboxylic acid (MAC) and partly as demethylated carboxylic acid (DMAC). 
The main circulating metabolite in plasma is DMAC with elimination half-life of 2.45 
hours. The maximum serum concentration (Cmax) of this metabolite is 1670 ng/mL, 
which is achieved at 1-hour time (Tmax). The usual therapeutic prescription of 
Mebeverine is 135mg three times per day (maximum 405mg/day). In order to avoid 
potential side effect, this study administered the therapeutic dose of 135mg 30 minutes 
before 18F-FDG injection.  
 
 Hysocine-n-butylbromide is a spasmolytic agent thas has effect on the smooth 
muscles of gastrointestinal tract, genitourinary tract as well as biliary tract. It does not 
cross into the central nervous system as it in the form of quarternary ammonium 
derivative. Therefore, anticholinergic effects of central nervous system do not occur. 
However peripherally, it exerts anticholinergic action as a result from ganglionic 
blocking action within the visceral wall and antimuscarinic effect.  
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 As it formed as a quartenary ammonium compound, it is highly polar and only 
partially absorbed following oral ingestion (8%). After oral ingestion, the maximum 
plasma concentration (Cmax) of this metabolite is around 0.11ng/ml, which 
approximately achieved at 2-hours time (Tmax). Following oral ingestion of single dose, 
the terminal elimination half-life is about 6.2 hours. The main metabolic pathway is 
hydrolysis of the ester bond that is later excreted in the faeces (approximately 90%) and 
urine (approximately 2-5%). The therapeutic prescription of oral Hyoscine is 10mg 3-5 
times per day with maximum dose of 60mg per day. Similarly, the lowest therapeutic 
dose of 10mg 30 minutes before 18F-FDG injection was chosen for this study to avoid 
potential side effects. 
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Table 2.5.1: The profiles of oral Mebeverine and Hyoscine-n-butylbromide 
 Duspatalin Buscopan 
Content Mebeverine hydrochloride Hyoscine-N-butylbromide 
Indication Symptomatic treatment of 
abdominal pain and cramps, 
bowel disturbances and 
abdominal discomfort related 
to irritable bowel syndrome. 
Treatment of gastrointestinal 
spasm secondary to organic 
diseases 
 
Gastrointestinal tract spasm 
and dyskinesia of the biliary 
system spasm, genitourinary 
tract spasm. 
Overdosage Theoretically, CNS 
excitability maybe predicted. 
No antidote. Gastric lavage 
and symptomatic treatment is 
recommended. 
Anticholinergic effects 
maybe observed. 
Treatment: 
Parasympathomimetic drugs 
should be administered. 
 
Contraindication Hypersensitivitiy Hypersensitivity 
Myasthenia gravis, 
megacolon 
 
Side effect None known Anticholinergic effects 
 
Mechanism of action Antispasmodic agent: 
Mebeverine is a 
musculotropic 
antispasmodic, with a direct 
action on the smooth muscle 
of the gastrointestinal tract, 
relieving spasm without 
affecting normal gut motility. 
Since this action is not 
mediated by the autonomic 
nervous system, the usual 
anticholinergic effect maybe 
absent. 
 
Pharmacokinetics: 
Rapidly and completely 
absorbed after oral 
administration. Metabolized 
completely before excretion. 
Hydrolysis of mebeverine 
leading to veratric acid and 
mebeverine alcohol that will 
be both excreted in the urine. 
Antispasmodic agent: 
Spasmolytic action against 
smooth muscle of 
gastrointestinal tract, 
genitourinary tract and 
biliary tract. 
Does not enter CNS. 
Peripheral anticholinergic 
action results from ganglion 
blocking action within the 
visceral wall and 
antimuscarinic activity. 
 
Pharmacokinetics: 
Absorbed as quarternary 
ammonium compound. 
Highly polar, therefore only 
partially absorbed following 
oral administration (8%). 
Main metabolic pathway is 
hydrolytic cleavage of ester 
bond. Excreted in the feces 
and the urine. 
 
Administration Taken 20-30 minutes before 
meal. 
Taken 20-30 minutes before 
meal. 
MIMS Malaysia (2017). Buscopan: Full Prescribing Info. [Online] Available from: 
http://www.mims.com/malaysia/drug/info/buscopan/?type=full [Accessed 13 August 2017]. 
 
MIMS Malaysia (2017). Buscopan: Full Prescribing Info. [Online] Available from: 
http://www.mims.com/malaysia/drug/info/duspatalin/?type=full [Accessed 13 August 2017].
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CHAPTER 3 
OBJECTIVES, HYPOTHESES AND RESEARCH FRAMEWORK 
 
3.1 General objective 
 To determine the effect of Mebeverine and Hyoscine-n-butylbromide in 
reducing physiological bowel uptake during 18F-FDG PET-CT. 
 
3.2 Specific objectives 
1. To compare SUVmean of bowel and bowel-to-liver ratio among patients 
receiving Mebeverine, Hyoscine and Control group 
2. To compare the degree of bowel uptake and difficulty of image 
interpretation among patients receiving Mebeverine, Hyoscine and Control 
group 
3. To determine the relationship between the degree of bowel uptake and 
difficulty of image interpretation 
 
3.3 Null hypothesis 
 There is no significant effect of Mebeverine and Hyoscine-n-butylbromide to 
reduce physiological bowel uptake in 18F-FDG PET-CT. 
 
 
3.4 Alternative hypothesis 
 There is significant effect of Mebeverine and Hyoscine-n-butylbromide to 
reduce physiological bowel uptake in 18F-FDG PET-CT. 
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3.5 Research framework 
 
Patient referred for 18-F FDG PET/CT in HPP!
Inclusion and !
exclusion criteria!
Grouping into either A, B or C !
Group A! Group B!
Tab Duspatalin 135mg 
30 minutes before 
tracer injection!
PET/CT scan!
Tracer injection!
Analysis !
Group C!
Tab Buscopan 10mg 
30 minutes before 
tracer injection!
 
* Tracer = 18F-FDG 
Duspatalin = brand name for Mebeverine 
Buscopan = brand name for Hyoscine-n-butylbromide 
 
 
 
 
 
Patient referred for 18F-FDG PE -CT 
*	
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CHAPTER 4 
METHODOLOGY 
4.1 Study location 
PET-CT Unit, Department of Nuclear Medicine, Penang Hospital. 
 
4.2 Study design and ethical approval 
This is a prospective, randomised controlled trial. 
This study obtained approval from two ethical boards as follows: 
1. Human Research Ethics Committee, Universiti Sains Malaysia (USM): 
JEPeM Code: USM/JEPeM/16010034. 
2. Medical Research and Ethics Committee, Ministry of Health Malaysia: 
Reference code: NMRR-16-1228-31786 (IIR). 
 
4.3 Study period 
Patient recruitment was done in between 1st September 2016 until 28th February 2017. 
 
4.4 Sampling 
 4.4.1 Source population 
All patients referred for PET/CT in Penang Hospital 
4.4.2  Study subjects 
All patients attending PET/CT in Penang Hospital who consented to take 
part in this study 
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4.4.3 Sample size calculation 
  Alpha: 0.05, Power: 0.8 (80%), Std. Dev.: 0.73, Diff: 0.365 M: 1 
Calculated sample size: 64 
Addition of 10% drops out rate: 70 
Total subject: 210 (where 70 for each group). 
Reference: (Song et al., 2014) and (Emmott et al., 2008) 
 4.4.4 Sampling method 
Based on the above calculation, the calculated sample size was 64 
patients for each group. After considering 10% drop out rate, the total sample 
size for each group was 70 patients.  
 
There were 500 patients registered for PET-CT scan during the patient 
recruitment period. Systematic random sampling was done to get 210 patients to 
be included in this study. The first patient was numbered as 1 and every other 
numbers were chosen until 210 patients. Subsequently, simple random sampling 
was done to nominate the members of groups A (received Duspatalin), B 
(received Buscopan) and C (control). Random number table available in the 
book ‘Kaedah Penyelidikan Buku 1’	was used for this (Piaw, 2011). Therefore, 
70 patients were put in every group before further inclusion and exclusion 
criterias were evaluated. 
 
After considering the exclusion criterias, from the total of 70 patients 
nominated in each group, 62 patients were recruited in Mebeverine group; 68 
patients were recruited in Hyoscine group and 65 patients were in the Control 
group. The remaining patients who were not selected into this study were 
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diabetic on metformin therapy and another 5 gave history of diarrhoea a week 
before the scan. 
4.4.5 Inclusion criteria 
 Patient who went for 18F-FDG PET-CT scan with the age above 18 
years old 
4.4.6 Exclusion criteria 
1. Patient on Metformin, Lactulose, enema or laxatives 
2. Patient with history of diarrhoea or abdominal pain for the past 1 
week 
3. Patient who was known allergy to Mebeverine, Hyoscine, lactose or 
sucrose 
4. Patient who was known of myasthenia gravis, glaucoma and 
megacolon (determined based on history or previous medical record) 
 
4.5 Research protocol 
Patients were fasted for at least 6 hours prior to 18F-FDG injection. Patients’ 
weight and fasting blood glucose were recorded upon arrival. The acceptable glucose 
level for all patients was 8.0 mmol/L or lower. Mebeverine group patients were given 
oral Mebeverine 135mg while Hyoscine group patients were given oral Hyoscine-n-
butylbromide 10mg 30 minutes before 18F-FDG injection. The patients in Control 
group were given neither Mebeverine nor Hyoscine-n-butylbromide. They received 
intravenous 18F-FDG only. The dose of 18F-FDG is based on body weight ranging 
from 10-20 mCi (370-740 MBq). 
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  PET-CT scanning was done 45 minutes to 1 hour after 18F-FDG injection using 
a dedicated Discovery ST PET-CT scanner (General Electric Medical Systems, 
Waukesha, WI, USA). The scanner used Bismuth Germanium Oxide (BGO) crystals, 
detector field of view (DFOV) of 50 cm with 24 PET ring-detectors. The scan was done 
covering from the skull to mid-thigh. A contemporaneous low dose non-contrasted CT 
was also done by the same scanner with 100 mA and 120 kV. CT scan speed at 0.8 s per 
revolution with 3.75 mm slice thickness. Meanwhile PET acquisition was obtained at 6-
8 beds position with overlap of 3.270 mm and 3 minutes emission scan for each bed 
position. Images were reconstructed using an iterative ordered-subsets expectation 
maximisation (OSEM) algorithm with CT attenuation correction.  
  An experienced nuclear medicine physician who was blinded of the clinical data 
of the patients reviewed the images. The revision was done using GE Advantage 
Workstation (General Electric Medical Systems, Waukesha, WI, USA). The interpreter 
used visual analysis to evaluate the degree of bowel uptake and difficulty of image 
interpretation. The interpreter scored each aspect with number 0 to 2 scale (Table 4.5.1 
and Table 4.5.2). 
Table 4.5.1: Scoring scale in visual analysis on the degree of bowel uptake 
Score Description 
0 No significant bowel uptake compared to background liver uptake 
1 Mild bowel uptake compared to background liver uptake 
2 Severe bowel uptake compared to background liver uptake 
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Table 4.5.2: Scoring scale in visual analysis on the difficulty in image interpretation 
Score Description 
0 No difficulty to interpret as physiological uptake 
1 Slight difficulty to interpret as physiological uptake 
2 Most difficult to interpret as physiological uptake 
   
  At the same time, the interpreter also semiquantitatively analysed the images by 
measuring SUV. The interpreter drew a region of interest (ROI) at the bowel area with 
highest uptake and the computer calculated the SUVmean at this area. The area of bowel 
with highest SUVmean is taken for statistical analysis later. Similarly in the liver, the 
same size of ROI was drawn for the computer to calculate the highest SUVmean of liver. 
All the relevant data collected from the analysis was recorded in a data collection form 
(Appendix E). 
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Figure 4.5.1: Example of maximum intensity projection of a patient with diffuse and 
intense uptake in the bowel with lower uptake in the liver. The interpreter scored 2 for 
degree of bowel uptake but scored 0 in the difficulty of bowel interpretation. This 
uptake was more likely physiological rather than pathological. This patient was from 
the Control group. 
 
 
 
